Monday, July 13, 2015
Can I Make Money Off the New Lens in My Eye?
Anyone who reads many of my posts know that I come up with unusual and obscure lists of stocks, lists such as candy and chocolate stocks, caffeine stocks, cord blood stocks, and cosmetic surgery stocks. Did you notice that all these examples begin with the letter 'C'? So here is another one, cataract stocks, the list of which can be found at WallStreetNewsNetwork.com.
A cataract is a clouding of the lens of the eye. Surprisingly, it is not just senior citizens that are afflicted with cataracts; people in their forties and fifties can have cataracts, according to the National Eye Institute of the National Institute of Health. The causes are numerous, everything from smoking to medications to ultraviolet light.
I started to do my research on the publicly traded cataract companies by looking at the manufacturers of the three different types of eyedrops that were prescribed for me. One, the Prednisolone Acetate, is distributed by Sandoz, a Novartis (NVS) company, the largest pharmaceutical company in the world by sales. However, the other two drops, Ketorolac Tromethamine and Ofloxacin, are made by a lessor known company, Akorn (AKRX).
Novartis is far from a pure play as it produces and market numerous types of pharmaceuticals for all types of treatments, not just eye care, plus they have extensive products in the animal health arena. The stock trades at a reasonable 12.6 times trailing earnings and 19.1 times forward earnings. It sports a yield of 2.7%.
Akorn is a $5 billion manufacturer and seller of prescription pharmaceuticals. The stock has a price to earnings ratio in the nosebleed area of 131 but a forward PE of 18.3. Potential investors should be aware that the company received a NASDAQ Delisting Notice for not filing its Form 10-Q on time.
Let's get to the nitty-gritty. STAAR Surgical Company (STAA) is a developer and manufacturer of the implantable lenses for the eye, along with the lens delivery systems. The company is currently generating negative earnings. Revenues for the latest quarter were down 6.6% year-over-year.
Keep an eye on these stocks. Keep them in your sight. Maybe you will see a good one on the free list of cataract stocks at WallStreetNewsNetwork.com.
Disclosure: Author didn't own any of the above at the time the article was written.
Action Alerts PLUS: Jim Cramer and Jack Mohr
Exclusive Offer - Check out Jim Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Take a look inside and receive Jim Cramer's newest book "Get Rich Carefully" at TheStreet.com.